Coley, HM; Safuwan, NA; Chivers, P; Papacharalbous, E; Giannopoulos, T; Butler-Manuel, S; Madhuri, K; Lovell, DP; Crook, T (2012) The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer. BRITISH JOURNAL OF CANCER, 106 (3). 482 - 489 (8). ISSN 0007-0920 https://doi.org/10.1038/bjc.2011.566
SGUL Authors: Lovell, David

Preview

["document_typename_application/pdf; charset=binary" not defined] Published Version Download (550kB) | Preview

Item Type:	Article
Additional Information:	PubMed ID: 22233925
Keywords:	Antineoplastic Agents, Carboplatin, Cell Line, Tumor, Cyclin-Dependent Kinase Inhibitor p27, DNA Methylation, Dose-Response Relationship, Drug, Down-Regulation, Drug Resistance, Neoplasm, Epigenesis, Genetic, Female, Humans, Ovarian Neoplasms, Purines, Science & Technology, Life Sciences & Biomedicine, Oncology, ovarian cancer, p57(Kip2), epigenetically silenced, carboplatin resistance, seliciclib, EXPRESSION, METHYLATION, P27(KIP1), SURVIVAL, AGENTS, CELLS, GENE, P53, D1, ovarian cancer, p57(Kip2), epigenetically silenced, carboplatin resistance, seliciclib
SGUL Research Institute / Research Centre:	Academic Structure > Institute of Medical & Biomedical Education (IMBE) Academic Structure > Institute of Medical & Biomedical Education (IMBE) > Centre for Biomedical Education (INMEBE)
Journal or Publication Title:	BRITISH JOURNAL OF CANCER
ISSN:	0007-0920
Dates:	Date Event 31 January 2012 Published
Web of Science ID:	WOS:000300302300009
	Download EPMC Full text (PDF)
	Download EPMC Full text (HTML)
URI:	https://openaccess.sgul.ac.uk/id/eprint/101427
Publisher's version:	https://doi.org/10.1038/bjc.2011.566

Actions (login required)

Edit Item